Johnson & Johnson Aktie News

The plaintiff's law firm said was the largest-ever sum awarded against J&J for a single plaintiff.

Coca-Cola has increased its dividend for 63 straight years. Johnson & Johnson has matched Coca-Cola's dividend growth streak.

A Baltimore jury ordered Johnson & Johnson and its subsidiaries to pay over $1.5 billion to a woman who claimed decades of exposure to asbestos in the company's talc-based products caused her peritoneal mesothelioma, a form of cancer.

BALTIMORE--(BUSINESS WIRE)--A Baltimore city jury has returned a verdict in favor of Cherie A. Craft, awarding her over $1.5 billion after finding that Johnson & Johnson and its subsidiaries exposed her to asbestos through talc-based personal care products and caused her to develop peritoneal malignant mesothelioma, an incurable cancer. The verdict is believed to be the largest ever returned ag...

A Minnesota jury awarded $65.5 million on Friday to a mother of three who claimed talcum products made by Johnson & Johnson exposed her to asbestos and contributed to her developing cancer in the lining of her lungs.

ST. PAUL, Minn.--(BUSINESS WIRE)--A Minnesota jury awarded $65.5 million to a 37-year-old mother of three minor children after finding in her favor in a lawsuit against Johnson & Johnson, concluding that the company's talc products exposed her to asbestos and contributed to her developing mesothelioma, a cancer of the lining of the lungs. The verdict follows a 13-day trial in Ramsey County Dist...

- TRUFILL n-BCA is now indicated for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and Chronic Subdural Hematoma (cSDH) as an adjunct to surgery. - Approval builds on a trusted solution in neurovascular embolization for over 25 years.

Johnson & Johnson is rated a buy, with accelerating revenue and earnings growth driven by TREMFYA, CARVYKTI, and robust MedTech innovation. JNJ's portfolio reshaping (divesting Orthopaedics and focusing on premium cardiovascular and vision franchises) should enhance margins and long-term growth prospects. TREMFYA's rapid adoption in IBD and the anticipated 2026 launch of icotrokinra position JN...